We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mesothelioma Diagnosis Improved with New Biomarkers

By LabMedica International staff writers
Posted on 27 Oct 2010
Print article
Three important biomarkers have emerged for less invasive diagnosis of the asbestos-linked cancer mesothelioma.

Levels of a protein biomarker called mesothelin, which is found in the pleural fluid of patients with malignant mesothelioma, were studied. Mesothelin is a protein produced by mesothelioma cells and released into the fluid around the lungs.

Compared with cytology, pleural-fluid mesothelin had better sensitivity, similar specificity, and superior negative predictive value. "Pleural effusion … can be maddeningly difficult to diagnose, as a wide variety of malignant and benign causes exist,” noted Helen E. Davies, M.D., from the Oxford Pleural Unit, Oxford Center for Respiratory Medicine, University of Oxford (Oxford, United Kingdom) "One of the causes, malignant pleural mesothelioma, is a relatively rare cancer, but its incidence is rapidly increasing on a global scale.”

Calretinin is a vitamin-D dependent calcium-binding protein and another well-established immunohistochemical marker for malignant mesothelioma. A group of German researchers developed an enzyme-linked immunosorbent assay (ELISA) blood test of calretinin and tested it on 97 healthy volunteers, 35 asbestos-exposed workers and 42 mesothelioma patients. Calretinin levels were found to be elevated in both the asbestos-exposed group and among those with mesothelioma. This study appeared in the journal BMC Cancer on May 28, 2010.

A more recent report noted that the calretinin test might not be as helpful in patients who have the rare sarcomatoid type of pleural mesothelioma. A group of Danish researchers cautioned that most sarcomatoid-mesothelioma cases test negative for the presence of calretinin. Their findings were published in the September 27, 2010 edition of Ugeskr Laeger.

University of Pisa (Italy) investigators examined the value of another potential diagnostic biomarker called osteopontin, found in the plasma and serum of mesothelioma patients. After testing for osteopontin in 94 healthy volunteers, 113 patients with benign respiratory diseases (BRD) and 32 patients with malignant pleural mesothelioma, the team found levels to be "significantly higher” in patients with malignant mesothelioma than in either the healthy control group or those with BRD. The report appeared ahead of print in the September 27, 2010, edition of the International Journal of Biological Markers. The authors wrote, "Plasma and serum osteopontin may be useful markers in the diagnosis of epithelial MPM in addition to traditional radiological exams.”

Mesothelioma is very difficult to diagnose as it mimics many other conditions. It needs to be recognized early in order to treat patients appropriately and produce better outcomes. These three biomarkers should help to diagnose the dangerous condition.

Related Links:

University of Oxford
University of Pisa



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more